Related Experiment Video
Updated: Aug 26, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Prevention of embolic complications in nonvalvular atrial fibrillation in the elderly
1National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado.
Insights
Prophylactic anticoagulation significantly reduces stroke risk in elderly patients with nonvalvular atrial fibrillation. Long-term therapy is recommended indefinitely for stroke prevention, pending further research on optimal duration and patient subgroups.
Area of Science:
- Cardiology
- Geriatrics
- Neurology
Background:
- Atrial fibrillation is prevalent in the elderly, often coexisting with heart disease.
- Nonvalvular atrial fibrillation elevates morbidity and mortality, primarily from embolic events like stroke.
- It increases stroke risk by 5.6-fold compared to age-matched individuals.
Purpose of the Study:
- To evaluate the efficacy of prophylactic anticoagulation in reducing stroke risk.
- To assess the safety and benefits of anticoagulation versus aspirin in elderly patients.
- To identify predictors of embolic risk and determine optimal long-term management strategies.
Main Methods:
- Review of three recent clinical trials on prophylactic anticoagulation.
- Comparison of outcomes between anticoagulation (full/partial) and aspirin.
- Analysis of stroke risk factors and complication rates.
Main Results:
- Prophylactic anticoagulation, both full and partial, significantly lowers stroke rates.
- Aspirin prophylaxis shows unclear benefits, with no proven effect in the elderly.
- Current methods cannot reliably predict embolic risk beyond previous embolism.
Conclusions:
- All nonvalvular atrial fibrillation patients warrant consideration for prophylactic anticoagulants.
- Therapy should generally be continued indefinitely due to persistent stroke risk.
- Further research is needed to refine risk stratification and optimize anticoagulation strategies.
Abstract:
Atrial fibrillation is common in elderly subjects, usually with coexistent underlying heart disease. Nonvalvular atrial fibrillation is associated with increased morbidity and mortality, especially due to embolic complications: it carries a 5.6-fold increased risk of stroke, compared with age-matched controls. Three recent trials have demonstrated that prophylactic anticoagulation (either 'full' or 'partial') decreases the rate of stroke significantly, with an acceptably low rate of complications. The benefits of aspirin prophylaxis are less clear, and currently there is no evidence for a beneficial effect in the elderly patient. At present, no factor apart from a previous symptomatic embolism predicts those who are at risk of embolism. The risk of stroke appears to continue for a long time and, until data are provided, therapy should be continued indefinitely in the absence of contraindications. All patients with nonvalvular atrial fibrillation should be considered for prophylactic anticoagulants. Further work is required to identify those at highest risk, and to clarify how long therapy should be continued and whether there are subgroups in whom full or partial anticoagulation would be preferable.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Coronary Artery Disease IV: Preventive Measures
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism III: Nursing Management

